What's in Nanjing Chia-tai Tianqing Pharmaceutical's pipeline?

Nanjing Chia-tai Tianqing Pharmaceutical has 9 drugs in our index: 1 marketed, 0 filed, 3 in Phase 3, 0 in Phase 2, 5 in Phase 1.

Which companies overlap with Nanjing Chia-tai Tianqing Pharmaceutical's portfolio?

Top competitors by shared drug class: AstraZeneca, B. Braun Melsungen AG, BeOne Medicines, Chong Kun Dang Pharmaceutical, Dong-A ST Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/nanjing-chia-tai-tianqing-pharmaceutical.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-18 · How we verify

Nanjing Chia-tai Tianqing Pharmaceutical — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nanjing Chia-tai Tianqing Pharmaceutical pipeline: 1 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 3 Phase 3 0 Phase 2 5 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
succinylated gelatin injection	succinylated gelatin injection	marketed	Colloid plasma volume expander		Critical Care / Anesthesia
Obeticholic Acid Tablets（OCA）	Obeticholic Acid Tablets（OCA）	phase 3	Farnesoid X receptor (FXR) agonist	FXR (Farnesoid X Receptor)	Hepatology / Gastroenterology
NTQ1062+Fulvestrant	NTQ1062+Fulvestrant	phase 3	Estrogen receptor degrader / Estrogen receptor antagonist combination	Estrogen receptor alpha (ERα)	Oncology
Placebo + fulvestrant	Placebo + fulvestrant	phase 3	Selective Estrogen Receptor Degrader (SERD)	Estrogen Receptor (ER)	Oncology

Therapeutic area mix

Oncology · 2
Critical Care / Anesthesia · 1
Hepatology / Gastroenterology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

AstraZeneca · 1 shared drug class
B. Braun Melsungen AG · 1 shared drug class
BeOne Medicines · 1 shared drug class
Chong Kun Dang Pharmaceutical · 1 shared drug class
Dong-A ST Co., Ltd. · 1 shared drug class
Genor Biopharma Co., Ltd. · 1 shared drug class
Hanmi Pharmaceutical Company Limited · 1 shared drug class
Jiangsu HengRui Medicine Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Nanjing Chia-tai Tianqing Pharmaceutical:

Cite this brief

Drug Landscape (2026). Nanjing Chia-tai Tianqing Pharmaceutical — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nanjing-chia-tai-tianqing-pharmaceutical. Accessed 2026-05-18.